TruStain FcX™ PLUS (anti-mouse CD16/32) Antibody

Catalog# / Size	156603 / 50 µg 156604 / 500 µg
Clone	S17011E
Regulatory Status	RUO
Other Names	CD16, CD32
Isotype	Rat IgG2b, κ
Description	CD16 is the low affinity IgG Fc receptor III (FcR III) and CD32 is FcR II. CD16/CD32 are expressed on B cells, monocytes/macrophages, NK cells, granulocytes, mast cells, and dendritic cells. The Fc receptors bind antibody-antigen immune complexes and mediate adaptive immune responses. TruStain FcX™ PLUS is specific to the common epitope of CD16/CD32. It is useful for blocking non-specific binding of immunoglobulin to the Fc receptors and is more effective than TruStain FcX™.

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Rat
Purity	The antibody was purified by affinity chromatography.
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Concentration	0.5 mg/ml
Storage & Handling	The CD16/32 antibody solution should be stored undiluted between 2°C and 8°C.
Application	FC - *Quality tested*
Recommended Usage	For blocking of Fc receptors in flow cytometric analysis, pre-incubate the cells with TruStain FcX™ PLUS for 5-10 minutes, on ice, at 0.25 µg per 10^6 cells in a volume of 100 µl, prior to immunostaining. It is not necessary to wash the cells between the blocking and immunostaining steps.
Application Notes	Clone S17011E blocks both clone 93 and 2.4G2 also raised against mouse CD16/32

Product Citations

1. Zhou J, *et al.* 2021. J Immunother Cancer. 9:. PubMed
2. Driscoll J, *et al.* 2021. Curr Protoc. 1:e249. PubMed
3. Fu R, *et al.* 2020. Sci Rep. 10:1455. PubMed
4. Bian L, *et al.* 2022. Front Immunol. 13:938598. PubMed
5. Thomas AM, *et al.* 2022. J Neuroinflammation. 19:130. PubMed
6. Uzhachenko RV, *et al.* 2021. Cell Reports. 35(1):108944. PubMed
7. Rodriguez-García A, *et al.* 2021. Nat Commun. 12:877. PubMed
8. Toomer G, *et al.* 2022. Viruses. 14:. PubMed
9. Oliva Chávez AS, *et al.* 2021. Nat Commun. 12:3696. PubMed
10. Music A, *et al.* 2022. Front Cell Dev Biol. 10:987148. PubMed
11. Kienzl M, *et al.* 2020. Oncoimmunology. 9:1776059. PubMed
12. Westphal A, *et al.* 2017. J Exp Med. 214:227. PubMed
13. Geng T, *et al.* 2022. Methods Mol Biol. 2585:71. PubMed
14. Chen X, *et al.* 2022. J Appl Oral Sci. 30:e20220316. PubMed
15. Ikeda S, *et al.* 2022. Sci Rep. 12:11564. PubMed
16. Thinard R, *et al.* 2022. Pharmaceutics. 14:. PubMed
17. So EY, *et al.* 2021. Am J Physiol Cell Physiol. 321:C569. PubMed
18. Wang JC, *et al.* 2022. Elife. 11:. PubMed
19. Zeng W, *et al.* 2021. STAR Protocols. 2(1):100361. PubMed
20. Oguri Y, *et al.* 2020. Cell. 182(3):563-577.e20. PubMed
21. Dong L, *et al.* 2022. Cells. 11:. PubMed
22. Pathania AS, *et al.* 2022. Mol Ther Oncolytics. 25:308. PubMed

23. Ejima R, *et al.* 2021. Nutrients. 13:. PubMed
24. Guo S, *et al.* 2021. Sci Rep. 11:23745. PubMed
25. Gomez S, *et al.* 2022. J Immunother Cancer. 10:. PubMed
26. Grubiši? V, *et al.* 2020. Cell Rep. 32:108100. PubMed
27. Galani IE, *et al.* 2022. STAR Protoc. 3:101151. PubMed
28. Olson B, *et al.* 2021. Brain Behav Immun. 97:102. PubMed
29. Chakraborty M, *et al.* 2021. Cell Reports. 34(2):108609. PubMed
30. Montel-Hagen A, *et al.* 2022. Curr Protoc. 2:e403. PubMed
31. Chen AF, *et al.* 2022. Nat Methods. 19:547. PubMed
32. Rocha-Resende C, *et al.* 2020. JCI Insight. 5:00. PubMed
33. Kos S, *et al.* 2019. PLoS One. 14:e0217762. PubMed
34. Li N, *et al.* 2022. Nat Commun. 13:7281. PubMed
35. Chen S, *et al.* 2022. iScience. 25:105176. PubMed
36. Oya Y, *et al.* 2021. Front Immunol. 12:779709. PubMed
37. Hobbs BE, *et al.* 2021. Pathogens. 10:. PubMed
38. Alhudaithi SS, *et al.* 2020. Mol Pharm. 17:4691. PubMed
39. Fan ZP, *et al.* 2021. Front Immunol. 12:743354. PubMed
40. Phan TS, *et al.* 2021. Sci Adv. 7:. PubMed
41. Casselli T, *et al.* 2021. PLoS Pathog. 17:e1009256. PubMed
42. Jiang Y, *et al.* 2021. Nat Commun. 12:742. PubMed
43. Madsen CS, *et al.* 2022. Commun Biol. 5:888. PubMed
44. Liu Q, *et al.* 2021. Adv Mater. 33:e2102852. PubMed
45. Beyer AI, *et al.* 2017. Stem Cells Dev. 26:102. PubMed
46. Van Winkle JA, *et al.* 2020. J Virol. 94:. PubMed
47. Wang Y, *et al.* 2021. Nature. 599:308. PubMed
48. Wang X, *et al.* 2021. Sci Transl Med. 13:. PubMed
49. Gardner A, *et al.* 2022. J Immunother Cancer. 10:. PubMed
50. Xu L, *et al.* 2022. Front Immunol. 13:841141. PubMed
51. Matsuda A, *et al.* 2020. J Appl Toxicol. 40:706. PubMed
52. Badgujar DC, *et al.* 2020. PLoS Pathog. 16:e1009016. PubMed
53. Celias DP, *et al.* 2022. STAR Protoc. 3:101464. PubMed

RRID

AB_2783137 (BioLegend Cat. No. 156603)
AB_2783138 (BioLegend Cat. No. 156604)

Antigen Details

Structure	Ig superfamily, 40-60 kD
Distribution	B cells, monocyte/macrophages, NK cells, neutrophils, mast cells, dendritic cells
Ligand/Receptor	IgG
Cell Type	B cells, Dendritic cells, Macrophages, Mast cells, Monocytes, Neutrophils, NK cells
Biology Area	Immunology
Molecular Family	CD Molecules, Fc Receptors
Gene ID	14130 14131

Related Protocols

Cell Surface Flow Cytometry Staining Protocol

Other Formats

TruStain FcX™ PLUS (anti-mouse CD16/32), APC/Cyanine7 anti-mouse CD16/32, PE/Cyanine7 anti-mouse CD16/32, PE anti-mouse CD16/32, APC anti-mouse CD16/32, FITC anti-mouse CD16/32 Antibody, PE/Dazzle™ 594 anti-mouse CD16/32 Antibody, PerCP/Cyanine5.5 anti-mouse CD16/32 Antibody, PE/Cyanine5 anti-mouse CD16/32, Alexa Fluor® 700 anti-mouse CD16/32, APC/Fire™ 750 anti-mouse CD16/32

Product Data



BALB/c splenocytes were incubated with TruStain FcX™ PLUS (clone S17011E, 0.25µg/10^6 cells, filled histogram) or TruStain FcX™ (clone 93, 1µg/10^6 cells, red line histogram) to block the Fc receptors, or were left untreated (black line histogram); then stained with CD90.2 (Thy-1.2, clone 53-2.1) FITC. Note the high background in the untreated cells and the bigger reduction in the background staining when the cells were incubated with TruStain FcX™ Plus compared to TruStain FcX™.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587